ITIF

Economic Consequences of Section 232 Tariffs on Semiconductor Imports
The Trump administration has imposed tariffs on semiconductor imports on national security grounds under Section 232 of the Trade Expansion Act. These tariffs would raise ICT prices and thereby lower ICT consumption and capital stocks, which would reduce economic growth and lower Americans’ living standards.

Declining Manufacturing Births Contribute to US Manufacturing Woes
Manufacturing start-ups, particularly in critical national economic power industries, are essential to the nation’s economic and security strength. Yet, U.S. manufacturing start-ups have declined over the last three decades.

Mobilizing for Techno-Economic War, Part 5: Transforming STEM Research Policy
Increased federal funding for STEM research is necessary but not sufficient for America to avoid losing to China. It’s also time for a new model for federal research funding that focuses on the technology needs of national power industries and directly benefits firms in the United States.
Comfortable Decline: How Canada Chooses Stability Over Dynamic Prosperity

Canadian innovation, productivity, and competitiveness are weak. Absent serious policy change, they will likely get even weaker. A turnaround requires addressing Canada’s core challenges—most fundamentally, a Canadian political economy that is not designed for the techno-economic environment the country now faces.
Mobilizing for Techno-Economic War, Part 2: Slowing China’s Advance

Boosting U.S. competitiveness in national power industries is necessary, but not sufficient to avoid losing to China. America also must take measures to slow the PRC’s progress toward global dominance. This report provides more than 100 actionable recommendations for the administration and Congress. Western allies should take many of the same steps.
Lessons From Europe’s Loss of Biopharma Leadership, and Its Attempts to Recover

Europe once led the world in biopharmaceutical innovation, but it lost ground after adopting policies that weakened incentives for R&D and innovation. America must learn from Europe’s experience to preserve its own biopharma leadership and the related economic benefits and access to the most innovative drugs.




















